Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

CD34+ chimerism analysis for minimal residual disease monitoring after allogeneic hematopoietic cell transplantation.

Unnikrishnan A, Meacham AM, Goldstein SS, Ta M, Leather HL, Cogle CR, Castillo P, Wingard JR, Norkin M.

Leuk Res. 2018 Nov;74:110-112. doi: 10.1016/j.leukres.2018.10.007. Epub 2018 Oct 18. No abstract available.

PMID:
30401521
2.

Functional genomic landscape of acute myeloid leukaemia.

Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, Carlos A, Carpenter R, Carroll J, Chang BH, Coblentz C, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Devine D, Dibb J, Edwards DK 5th, Eide CA, English I, Glover J, Henson R, Ho H, Jemal A, Johnson K, Johnson R, Junio B, Kaempf A, Leonard J, Lin C, Liu SQ, Lo P, Loriaux MM, Luty S, Macey T, MacManiman J, Martinez J, Mori M, Nelson D, Nichols C, Peters J, Ramsdill J, Rofelty A, Schuff R, Searles R, Segerdell E, Smith RL, Spurgeon SE, Sweeney T, Thapa A, Visser C, Wagner J, Watanabe-Smith K, Werth K, Wolf J, White L, Yates A, Zhang H, Cogle CR, Collins RH, Connolly DC, Deininger MW, Drusbosky L, Hourigan CS, Jordan CT, Kropf P, Lin TL, Martinez ME, Medeiros BC, Pallapati RR, Pollyea DA, Swords RT, Watts JM, Weir SJ, Wiest DL, Winters RM, McWeeney SK, Druker BJ.

Nature. 2018 Oct;562(7728):526-531. doi: 10.1038/s41586-018-0623-z. Epub 2018 Oct 17.

PMID:
30333627
3.

CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia.

Garcia-Manero G, Scott BL, Cogle CR, Boyd TE, Kambhampati S, Hetzer J, Dong Q, Kumar K, Ukrainskyj SM, Beach CL, Skikne BS.

Leuk Res. 2018 Sep;72:79-85. doi: 10.1016/j.leukres.2018.08.001. Epub 2018 Aug 3.

4.

Exploring the Structure-Activity Relationship and Mechanism of a Chromene Scaffold (CXL Series) for Its Selective Antiproliferative Activity toward Multidrug-Resistant Cancer Cells.

Bian T, Chandagirikoppal Vijendra K, Wang Y, Meacham A, Hati S, Cogle CR, Sun H, Xing C.

J Med Chem. 2018 Aug 9;61(15):6892-6903. doi: 10.1021/acs.jmedchem.8b00813. Epub 2018 Jul 25.

5.

Using social media to assess care coordination goals and plans for leukemia patients and survivors.

Strekalova YA, Hawkins KE, Drusbosky LM, Cogle CR.

Transl Behav Med. 2018 May 23;8(3):481-491. doi: 10.1093/tbm/ibx075.

PMID:
29800400
6.

Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation.

Davies JK, Brennan LL, Wingard JR, Cogle CR, Kapoor N, Shah AJ, Dey BR, Spitzer TR, de Lima M, Cooper LJ, Thall PF, Champlin RE, Nadler LM, Guinan EC.

Clin Cancer Res. 2018 Sep 1;24(17):4098-4109. doi: 10.1158/1078-0432.CCR-18-0449. Epub 2018 May 16.

PMID:
29769208
7.

Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia.

Norkin M, Katragadda L, Zou F, Xiong S, Chang M, Dai Y, Hsu JW, Moreb JS, Leather H, Murthy HS, Farhadfar N, Li Y, Hromas R, Brown RA, Cogle CR, Wingard JR.

Blood Cancer J. 2017 Nov 27;7(12):634. doi: 10.1038/s41408-017-0007-x.

8.

Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study.

Swords RT, Azzam D, Al-Ali H, Lohse I, Volmar CH, Watts JM, Perez A, Rodriguez A, Vargas F, Elias R, Vega F, Zelent A, Brothers SP, Abbasi T, Trent J, Rangwala S, Deutsch Y, Conneally E, Drusbosky L, Cogle CR, Wahlestedt C.

Leuk Res. 2018 Jan;64:34-41. doi: 10.1016/j.leukres.2017.11.008. Epub 2017 Nov 11.

9.

Refractory macrocytic anemias in patients with clonal hematopoietic disorders and isolated mutations of the spliceosome gene ZRSR2.

Fleischman RA, Stockton SS, Cogle CR.

Leuk Res. 2017 Oct;61:104-107. doi: 10.1016/j.leukres.2017.09.002. Epub 2017 Sep 8.

PMID:
28942350
10.

Computational Modeling and Treatment Identification in the Myelodysplastic Syndromes.

Drusbosky LM, Cogle CR.

Curr Hematol Malig Rep. 2017 Oct;12(5):478-483. doi: 10.1007/s11899-017-0412-z. Review.

11.

Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence.

Cogle CR, Reddy SR, Chang E, Papoyan E, Broder MS, McGuire M, Binder G.

Leuk Res. 2017 Sep;60:123-128. doi: 10.1016/j.leukres.2017.07.008. Epub 2017 Aug 1.

12.

Peripheral Blood Cytokine Levels After Acute Myocardial Infarction: IL-1β- and IL-6-Related Impairment of Bone Marrow Function.

Shahrivari M, Wise E, Resende M, Shuster JJ, Zhang J, Bolli R, Cooke JP, Hare JM, Henry TD, Khan A, Taylor DA, Traverse JH, Yang PC, Pepine CJ, Cogle CR; Cardiovascular Cell Therapy Research Network (CCTRN).

Circ Res. 2017 Jun 9;120(12):1947-1957. doi: 10.1161/CIRCRESAHA.116.309947. Epub 2017 May 10.

13.

The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail.

Cogle CR, Kurtin SE, Bentley TG, Broder MS, Chang E, Megaffin S, Fruchtman S, Petrone ME, Mukherjee S.

Oncologist. 2017 Apr;22(4):379-385. doi: 10.1634/theoncologist.2016-0211. Epub 2017 Mar 10.

14.

The role and clinical implications of the endosteal niche and osteoblasts in regulating leukemia.

Azizidoost S, Vijay V, Cogle CR, Khodadi E, Saki N.

Clin Transl Oncol. 2017 Sep;19(9):1059-1066. doi: 10.1007/s12094-017-1642-1. Epub 2017 Mar 9. Review.

PMID:
28281084
15.

Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patients.

Drusbosky L, Medina C, Martuscello R, Hawkins KE, Chang M, Lamba JK, Vali S, Kumar A, Singh NK, Abbasi T, Sekeres MA, Mallo M, Sole F, Bejar R, Cogle CR.

Leuk Res. 2017 Jan;52:1-7. doi: 10.1016/j.leukres.2016.11.004. Epub 2016 Nov 6.

16.

Circulating progenitor cells and coronary microvascular dysfunction: Results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation - Coronary Vascular Dysfunction Study (WISE-CVD).

Mekonnen G, Hayek SS, Mehta PK, Li Q, Mahar E, Mou L, Kenkre TS, Petersen JW, Azarbal B, Samuels B, Anderson RD, Sedlak T, Zaya M, Agarwal M, Haftbaradaran A, Minissian M, Handberg E, Pepine CJ, Cogle CR, Bairey Merz CN, Waller EK, Quyyumi AA.

Atherosclerosis. 2016 Oct;253:111-117. doi: 10.1016/j.atherosclerosis.2016.08.026. Epub 2016 Aug 26.

PMID:
27596135
17.

Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial.

Bhatnagar A, Bolli R, Johnstone BH, Traverse JH, Henry TD, Pepine CJ, Willerson JT, Perin EC, Ellis SG, Zhao DX, Yang PC, Cooke JP, Schutt RC, Trachtenberg BH, Orozco A, Resende M, Ebert RF, Sayre SL, Simari RD, Moyé L, Cogle CR, Taylor DA; Cardiovascular Cell Therapy Research Network (CCTRN).

Am Heart J. 2016 Sep;179:142-50. doi: 10.1016/j.ahj.2016.06.018. Epub 2016 Jul 6.

18.

Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.

Steensma DP, Abedi M, Bejar R, Cogle CR, Foucar K, Garcia-Manero G, George TI, Grinblatt D, Komrokji R, Ma X, Maciejewski J, Pollyea DA, Savona MR, Scott B, Sekeres MA, Thompson MA, Swern AS, Nifenecker M, Sugrue MM, Erba H.

BMC Cancer. 2016 Aug 19;16:652. doi: 10.1186/s12885-016-2710-6.

19.

An injectable capillary-like microstructured alginate hydrogel improves left ventricular function after myocardial infarction in rats.

Rocca DG, Willenberg BJ, Qi Y, Simmons CS, Rubiano A, Ferreira LF, Huo T, Petersen JW, Ruchaya PJ, Wate PS, Wise EA, Handberg EM, Cogle CR, Batich CD, Byrne BJ, Pepine CJ.

Int J Cardiol. 2016 Oct 1;220:149-54. doi: 10.1016/j.ijcard.2016.06.158. Epub 2016 Jun 25.

20.

Effect of melphalan 140 mg/m(2) vs 200 mg/m(2) on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience.

Katragadda L, McCullough LM, Dai Y, Hsu J, Byrne M, Hiemenz J, May S, Cogle CR, Norkin M, Brown RA, Wingard JR, Chang M, Moreb JS.

Clin Transplant. 2016 Aug;30(8):894-900. doi: 10.1111/ctr.12762. Epub 2016 Jun 29.

PMID:
27219740
21.

A new model to predict remission status in AML patients based on day 14 bone marrow biopsy.

Norkin M, Chang M, An Q, Leather H, Katragadda L, Li Y, Moreb JS, May WS, Brown RA, Hsu JW, Hiemenz JW, Wingard JR, Cogle CR.

Leuk Res. 2016 Jul;46:69-73. doi: 10.1016/j.leukres.2016.04.013. Epub 2016 Apr 20.

PMID:
27132034
22.

Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies.

Villa NY, Rahman MM, McFadden G, Cogle CR.

Viruses. 2016 Mar 22;8(3):85. doi: 10.3390/v8030085. Review.

23.

Chemosensitizing AML cells by targeting bone marrow endothelial cells.

Bosse RC, Wasserstrom B, Meacham A, Wise E, Drusbosky L, Walter GA, Chaplin DJ, Siemann DW, Purich DL, Cogle CR.

Exp Hematol. 2016 May;44(5):363-377.e5. doi: 10.1016/j.exphem.2016.02.003. Epub 2016 Feb 16.

PMID:
26898708
24.

Ex vivo virotherapy with myxoma virus does not impair hematopoietic stem and progenitor cells.

Villa NY, Bais S, Chan WM, Meacham AM, Wise E, Rahman MM, Moreb JS, Rosenau EH, Wingard JR, McFadden G, Cogle CR.

Cytotherapy. 2016 Mar;18(3):465-80. doi: 10.1016/j.jcyt.2015.12.007.

25.

Angiotensin II Regulation of Proliferation, Differentiation, and Engraftment of Hematopoietic Stem Cells.

Kim S, Zingler M, Harrison JK, Scott EW, Cogle CR, Luo D, Raizada MK.

Hypertension. 2016 Mar;67(3):574-84. doi: 10.1161/HYPERTENSIONAHA.115.06474. Epub 2016 Jan 18.

26.

Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN Trial.

Taylor DA, Perin EC, Willerson JT, Zierold C, Resende M, Carlson M, Nestor B, Wise E, Orozco A, Pepine CJ, Henry TD, Ellis SG, Zhao DX, Traverse JH, Cooke JP, Schutt RC, Bhatnagar A, Grant MB, Lai D, Johnstone BH, Sayre SL, Moyé L, Ebert RF, Bolli R, Simari RD, Cogle CR; Cardiovascular Cell Therapy Research Network (CCTRN).

Cell Transplant. 2016;25(9):1675-1687. Epub 2015 Nov 19.

27.

Cost-effectiveness of treatments for high-risk myelodysplastic syndromes after failure of first-line hypomethylating agent therapy.

Cogle CR, Ortendahl JD, Bentley TG, Anene AM, Megaffin S, McKearn TJ, Petrone ME, Mukherjee S.

Expert Rev Pharmacoecon Outcomes Res. 2016;16(2):275-84. doi: 10.1586/14737167.2016.1096200. Epub 2015 Nov 20.

PMID:
26589773
28.

Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Cogle CR, Scott BL, Boyd T, Garcia-Manero G.

Oncologist. 2015 Dec;20(12):1404-12. doi: 10.1634/theoncologist.2015-0165. Epub 2015 Oct 13. Review.

29.

Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes.

Garcia-Manero G, Gore SD, Kambhampati S, Scott B, Tefferi A, Cogle CR, Edenfield WJ, Hetzer J, Kumar K, Laille E, Shi T, MacBeth KJ, Skikne B.

Leukemia. 2016 Apr;30(4):889-96. doi: 10.1038/leu.2015.265. Epub 2015 Oct 7.

30.

Clinical significance of in vivo cytarabine-induced gene expression signature in AML.

Lamba JK, Pounds S, Cao X, Crews KR, Cogle CR, Bhise N, Raimondi SC, Downing JR, Baker SD, Ribeiro RC, Rubnitz JE.

Leuk Lymphoma. 2016;57(4):909-20. doi: 10.3109/10428194.2015.1086918. Epub 2015 Oct 16.

31.

Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.

Laille E, Shi T, Garcia-Manero G, Cogle CR, Gore SD, Hetzer J, Kumar K, Skikne B, MacBeth KJ.

PLoS One. 2015 Aug 21;10(8):e0135520. doi: 10.1371/journal.pone.0135520. eCollection 2015.

32.

Bone marrow niche in the myelodysplastic syndromes.

Cogle CR, Saki N, Khodadi E, Li J, Shahjahani M, Azizidoost S.

Leuk Res. 2015 Oct;39(10):1020-7. doi: 10.1016/j.leukres.2015.06.017. Epub 2015 Jul 14. Review.

PMID:
26276090
33.

Endothelial cell derived angiocrine support of acute myeloid leukemia targeted by receptor tyrosine kinase inhibition.

Drusbosky L, Gars E, Trujillo A, McGee C, Meacham A, Wise E, Scott EW, Cogle CR.

Leuk Res. 2015 Sep;39(9):984-9. doi: 10.1016/j.leukres.2015.05.015. Epub 2015 Jul 2.

34.

Incidence and Burden of the Myelodysplastic Syndromes.

Cogle CR.

Curr Hematol Malig Rep. 2015 Sep;10(3):272-81. doi: 10.1007/s11899-015-0269-y. Review.

35.

Acute myeloid leukemia in the vascular niche.

Cogle CR, Bosse RC, Brewer T, Migdady Y, Shirzad R, Kampen KR, Saki N.

Cancer Lett. 2016 Oct 1;380(2):552-60. doi: 10.1016/j.canlet.2015.05.007. Epub 2015 May 8. Review.

PMID:
25963886
36.

Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells.

Villa NY, Wasserfall CH, Meacham AM, Wise E, Chan W, Wingard JR, McFadden G, Cogle CR.

Blood. 2015 Jun 11;125(24):3778-88. doi: 10.1182/blood-2014-07-587329. Epub 2015 Apr 22.

37.

Vitamin D effect on umbilical cord blood characteristics: a comparison between African Americans and Caucasians.

Eldjerou LK, Cogle CR, Rosenau EH, Lu X, Bennett CA, Sugrue MW, Hoyne J, Lambert A, Ashley L, Sazama K, Fields G, Wingard JR, Zubair AC.

Transfusion. 2015 Jul;55(7):1766-71. doi: 10.1111/trf.13124. Epub 2015 Apr 22.

PMID:
25903156
38.

Two novel RUNX1 mutations in a patient with congenital thrombocytopenia that evolved into a high grade myelodysplastic syndrome.

Schmit JM, Turner DJ, Hromas RA, Wingard JR, Brown RA, Li Y, Li MM, Slayton WB, Cogle CR.

Leuk Res Rep. 2015 Apr 3;4(1):24-7. doi: 10.1016/j.lrr.2015.03.002. eCollection 2015.

39.

Prevention of EBV lymphoma development by oncolytic myxoma virus in a murine xenograft model of post-transplant lymphoproliferative disease.

Kim M, Rahman MM, Cogle CR, McFadden G.

Biochem Biophys Res Commun. 2015 Jul 10;462(4):283-7. doi: 10.1016/j.bbrc.2015.03.146. Epub 2015 Apr 2.

PMID:
25843801
41.

Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial.

Schutt RC, Trachtenberg BH, Cooke JP, Traverse JH, Henry TD, Pepine CJ, Willerson JT, Perin EC, Ellis SG, Zhao DX, Bhatnagar A, Johnstone BH, Lai D, Resende M, Ebert RF, Wu JC, Sayre SL, Orozco A, Zierold C, Simari RD, Moyé L, Cogle CR, Taylor DA; Cardiovascular Cell Therapy Research Network (CCTRN).

Circ Res. 2015 Jan 2;116(1):99-107. doi: 10.1161/CIRCRESAHA.116.304710. Epub 2014 Nov 18.

42.

Tandem Autologous Stem Cell Transplantation for Multiple Myeloma Patients Based on Response to Their First Transplant-A Prospective Phase II Study.

Byrne M, Salmasinia D, Leather H, Cogle CR, Davis A, Hsu JW, Wiggins L, Chang MN, An Q, Wingard JR, Moreb JS.

Clin Med Insights Oncol. 2014 Sep 3;8:101-5. doi: 10.4137/CMO.S16835. eCollection 2014.

43.

Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes.

Cogle CR, Wise E, Meacham AM, Zierold C, Traverse JH, Henry TD, Perin EC, Willerson JT, Ellis SG, Carlson M, Zhao DX, Bolli R, Cooke JP, Anwaruddin S, Bhatnagar A, da Graca Cabreira-Hansen M, Grant MB, Lai D, Moyé L, Ebert RF, Olson RE, Sayre SL, Schulman IH, Bosse RC, Scott EW, Simari RD, Pepine CJ, Taylor DA; Cardiovascular Cell Therapy Research Network (CCTRN).

Circ Res. 2014 Oct 24;115(10):867-74. doi: 10.1161/CIRCRESAHA.115.304353. Epub 2014 Aug 18.

44.

Mapping hematopoiesis in a fully regenerative vertebrate: the axolotl.

Lopez D, Lin L, Monaghan JR, Cogle CR, Bova FJ, Maden M, Scott EW.

Blood. 2014 Aug 21;124(8):1232-41. doi: 10.1182/blood-2013-09-526970. Epub 2014 May 6.

45.

Fishing for myelodysplastic syndromes finds uncaptured cases by state cancer registries: Need for more resources.

Cogle CR.

Cancer. 2014 Jun 1;120(11):1614-6. doi: 10.1002/cncr.28638. Epub 2014 Mar 18. No abstract available.

46.

Functional integration of acute myeloid leukemia into the vascular niche.

Cogle CR, Goldman DC, Madlambayan GJ, Leon RP, Masri AA, Clark HA, Asbaghi SA, Tyner JW, Dunlap J, Fan G, Kovacsovics T, Liu Q, Meacham A, Hamlin KL, Hromas RA, Scott EW, Fleming WH.

Leukemia. 2014 Oct;28(10):1978-1987. doi: 10.1038/leu.2014.109. Epub 2014 Mar 18.

47.

Radiation alone for solid tumors and the questionable development of therapy-related myelodysplastic syndromes.

Cogle CR.

J Natl Cancer Inst. 2014 Mar;106(3):dju025. doi: 10.1093/jnci/dju025. Epub 2014 Feb 27. No abstract available.

PMID:
24577814
48.

High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainment.

Cogle CR, Iannacone MR, Yu D, Cole AL, Imanirad I, Yan L, Mackinnon JA, List AF, Rollison DE.

Leuk Res. 2014 Jan;38(1):71-5. doi: 10.1016/j.leukres.2013.10.023. Epub 2013 Nov 5.

PMID:
24280283
49.

A critical analysis of clinical outcomes reported in stem cell trials for acute myocardial infarction: some thoughts for design of future trials.

Szady AD, Pepine CJ, Sharma SV, Cogle CR, Perin EC, Ellis SG, Moyé LA; Cardiovascular Cell Therapy Research Network (CCTRN).

Curr Atheroscler Rep. 2013 Aug;15(8):341. doi: 10.1007/s11883-013-0341-9. Review.

50.

PARP1 is required for chromosomal translocations.

Wray J, Williamson EA, Singh SB, Wu Y, Cogle CR, Weinstock DM, Zhang Y, Lee SH, Zhou D, Shao L, Hauer-Jensen M, Pathak R, Klimek V, Nickoloff JA, Hromas R.

Blood. 2013 May 23;121(21):4359-65. doi: 10.1182/blood-2012-10-460527. Epub 2013 Apr 8.

Supplemental Content

Loading ...
Support Center